Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 67749-67751 [2010-27728]

Download as PDF Federal Register / Vol. 75, No. 212 / Wednesday, November 3, 2010 / Notices noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 26, 2010. A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414: 1. Peoples Bancorp, Inc., Prairie du Chien, Wisconsin; to acquire 100 percent of the voting shares of Woodhouse & Bartley Bank, Bloomington, Wisconsin. B. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001: 1. Exchange Bancorp of Missouri, Inc., Fayette, Missouri; to become a bank holding company by acquiring 100 percent of the voting shares of Exchange Bank of Missouri, Fayette, Missouri. Board of Governors of the Federal Reserve System, October 28, 2010. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2010–27684 Filed 11–2–10; 8:45 am] BILLING CODE 6210–01–P FEDERAL MARITIME COMMISSION jlentini on DSKJ8SOYB1PROD with NOTICES Notice of Agreements Filed The Commission hereby gives notice of the filing of the following agreements under the Shipping Act of 1984. Interested parties may submit comments on the agreements to the Secretary, Federal Maritime Commission, Washington, DC 20573, within ten days of the date this notice appears in the Federal Register. Copies of the agreements are available through the Commission’s Web site (https:// www.fmc.gov) or by contacting the Office of Agreements at (202) 523–5793 or tradeanalysis@fmc.gov. Agreement No.: 001941–003. Title: Baltimore Marine Terminal Association. Parties: Ports Baltimore, Inc.; Maryland International Terminals, Inc.; Mid-Atlantic Terminal LLC; Ceres Marine terminals, Inc.; Tartan Terminals, Inc. and Ports America Chesapeake, Inc. Filing Party: JoAnne Zawitoski, Esq.; Baltimore Marine Terminal Association; 25 South Charles Street, Suite 1400, Baltimore, MD 21201. Synopsis: The amendment restates the agreement and identifies the current members of the BTMA. VerDate Mar<15>2010 19:21 Nov 02, 2010 Jkt 223001 Agreement No.: 011435–014. Title: APL/HLAG Space Charter Agreement. Parties: American President Lines, Ltd.; APL Co. Pte Ltd.; and Hapag-Lloyd AG. Filing Party: Wayne R. Rohde, Esq.; Cozen O’Connor; 1627 I Street, NW., Suite 1100, Washington, DC 20006. Synopsis: The amendment updates the corporate address for APL. Agreement No.: 011741–015. Title: U.S. Pacific Coast-Oceania Agreement. Parties: ANL Singapore PTE Ltd.; A.P. Moller-Maersk A/S; CMA CGM S.A.; ¨ Hamburg-Sud; and Hapag-Lloyd AG. Filing Party: Wayne R. Rohde, Esq.; Cozen O’Connor; 1627 I Street, NW., Suite 1100, Washington, DC 20006. Synopsis: The amendment increases the amount of space CMA CGM is allotted from Pacific Northwest ports. Agreement No.: 012077–001. Title: APL/Maersk Line Reciprocal Space Charter Agreement. Parties: American President Lines, Ltd.; APL Co. Pte, Ltd.; and A.P. Moller Maersk A/S. Filing Party: Eric. C. Jeffrey, Esq.; Counsel for APL; Goodwin Procter LLP; 901 New York Avenue, NW., Washington, DC 20001. Synopsis: The amendment updates the corporate addresses of American President Lines, Ltd. and APL Co. Pte Ltd. Agreement No.: 012108. Title: The World Liner Data Agreement. Parties: A.P. Moller-Maersk A/S; CMA CGM S.A.; Compania Chilena de Navegacion Interoceanica S.A.; Hamburg-Sud; Hapag-Lloyd AG; Orient Overseas Container Line Ltd.; and United Arab Shipping Company S.A.G. Filing Party: Wayne Rohde, Esq.; Cozen O’Connor; 627 I Street, NW., Suite 1100, Washington, DC 20006. Synopsis: The pending agreement has been changed to include CCNI and Orient Overseas Container Line Ltd as parties to the Agreement. Agreement No.: 201209. Title: Marine Terminal Lease and Operating Agreement Between Broward County and Seafreight Agencies (USA), Inc. Parties: Broward County and Seafreight Agencies (USA), Inc. Filing Party: Candace J. Running; Broward County Board of County Commissioners; Office of the County Attorney; 1850 Eller Drive, Suite 502, Fort Lauderdale, FL 33316. Synopsis: The agreement provides for the lease and operation of terminal facilities at Port Everglades in Broward County, Florida. PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 67749 By Order of the Federal Maritime Commission. Dated: October 29, 2010. Karen V. Gregory, Secretary. [FR Doc. 2010–27777 Filed 11–2–10; 8:45 am] BILLING CODE P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: The Department of Health and Human Services (HHS) notifies Federal agencies of the Laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently certified Laboratories and Instrumented Initial Testing Facilities (IITF) is published in the Federal Register during the first week of each month. If any Laboratory/ IITF’s certification is suspended or revoked, the Laboratory/IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any Laboratory/IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at https://www.workplace. samhsa.gov and https://www. drugfreeworkplace.gov. FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 2– 1042, One Choke Cherry Road, Rockville, Maryland 20857; 240–276– 2600 (voice), 240–276–2610 (fax). SUMMARY: E:\FR\FM\03NON1.SGM 03NON1 67750 Federal Register / Vol. 75, No. 212 / Wednesday, November 3, 2010 / Notices The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The ‘‘Mandatory Guidelines for Federal Workplace Drug Testing Programs,’’ as amended in the revisions listed above, requires {or set} strict standards that Laboratories and Instrumented Initial Testing Facilities (IITF) must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant Laboratory/IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a Laboratory/IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and Instrumented Initial Testing Facilities (IITF) in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A Laboratory/ IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/ NIDA) which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following Laboratories and Instrumented Initial Testing Facilities (IITF) meet the minimum standards to conduct drug and specimen validity tests on urine specimens: SUPPLEMENTARY INFORMATION: jlentini on DSKJ8SOYB1PROD with NOTICES Instrumented Initial Testing Facilities (IITF): None. Laboratories: ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328– 7840/800–877–7016 (Formerly: Bayshore Clinical Laboratory). ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264. Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290– 1150. Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210, 615– 255–2400 (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc.). Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504– 361–8989/800–433–3823 (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.). Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130 (Formerly: Kroll VerDate Mar<15>2010 19:21 Nov 02, 2010 Jkt 223001 Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.). Baptist Medical Center-Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center). Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800– 445–6917. Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671– 2281. DrugScan, Inc. P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974, 215–674–9310. DynaLIFE Dx *, 10150–102 St., Suite 200, Edmonton, Alberta, Canada T5J 5E2, 780–451–3702/800–661–9876 (Formerly: Dynacare Kasper Medical Laboratories). ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662–236–2609. Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519– 679–1630. Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288/ 800–800–2387. Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400/800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.). Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919– 572–6900/800–833–3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group). Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/800–233– 6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/ National Laboratory Center). LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845 (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.,). Maxxam Analytics*, 6740 Campobello Road, Mississauga, ON, Canada L5N 2L8, 905–817–5700 (Formerly: Maxxam Analytics Inc., NOVAMANN (Ontario), Inc.). PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651–636–7466/800–832–3244. MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950–5295. Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088. National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250/800–350– 3515. One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory). Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory). Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991/ 800–541–7891x7. Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858–643–5555. Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800–729–6432 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories). Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–4600/877–642–2216 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories). Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 91304, 800–877–2520 (Formerly: SmithKline Beecham Clinical Laboratories). S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505–727–6300/800–999–5227. South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x1276. Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602–438–8507/800– 279–0027. St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272–7052. Sterling Reference Laboratories, 2617 East L Street, Tacoma, Washington 98421, 800–442–0438. Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273. E:\FR\FM\03NON1.SGM 03NON1 Federal Register / Vol. 75, No. 212 / Wednesday, November 3, 2010 / Notices Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305– 593–2260. US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085. *The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHScertified laboratories and participate in the NLCP certification maintenance program. Dated: October 28, 2010. Elaine Parry, Director, Office of Management, Technology, and Operations, SAMHSA. [FR Doc. 2010–27728 Filed 11–2–10; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–5055–N] jlentini on DSKJ8SOYB1PROD with NOTICES Medicare Program: Community-Based Care Transitions Program (CCTP) Meeting Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice of meeting. AGENCY: This notice announces a public conference hosted by CMS. This conference will provide a forum for SUMMARY: VerDate Mar<15>2010 19:21 Nov 02, 2010 Jkt 223001 community-based organizations, hospitals, Quality Improvement Organizations, Administration on Aging grantees, and other healthcare providers to receive useful guidance and ask questions about the upcoming Community-based Care Transitions Program. The meeting is open to the public, but attendance is limited to space and Webinar lines available. DATES: Meeting Date: Friday, December 3, 2010, from 8 a.m. to 4 p.m., eastern standard time (e.s.t.). Deadline for Webinar or Web-based Registration: Thursday, December 2, 2010, 8 a.m., e.s.t. Deadline for Meeting Registration: Friday, November 19, 2010, 4 p.m., e.s.t. Limited walk-in registration may be available the evening prior to the conference and the morning of the conference as space permits. ADDRESSES: Meeting Location: Marriott Waterfront Hotel, 700 Aliceanna Street, Baltimore, MD 21202. Registration: The meeting is open to the public, but attendance is limited to space and Webinar lines available. A link to the agenda and registration information will be posted on the CMS Care Transitions Web site at https:// www.cms.gov/DemoProjectsEvalRpts/ MD/ itemdetail.asp?itemID=CMS1239313 as soon as it is available. Persons wishing to attend this meeting in person or via Webinar are encouraged to register in advance. Special Accommodations: Individuals who require special accommodations should send an e-mail request to CareTransitions@cms.hhs.gov or via regular mail to the address specified in the FOR FURTHER INFORMATION CONTACT section of this notice. Presentation materials will be posted on the CMS Care Transitions Web site prior to the meeting. FOR FURTHER INFORMATION CONTACT: Juliana Tiongson, Social Science Research Analyst, Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244–1850, Mail Stop C4–14–15, telephone 410– 786–0342 or e-mail Juliana.Tiongson@cms.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background Community-based organizations (CBOs) are defined in the statute as community-based organizations that provide care transition services across a continuum of care through arrangements with subsection (d) hospitals (as defined in section 1886(d)(1)(B) of the Social Security Act) and whose governing body includes PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 67751 sufficient representation of multiple health care stakeholders, including consumers. Experts in the field will present evidence-based care transition models, and lessons learned from participation in the Quality Improvement Organizations’ (QIOs) 9th scope of work care transitions subnational theme and related initiatives. Healthcare leaders will present broader, hospital-based interventions to reduce readmissions, as well as the positive financial implications of successfully reducing readmissions. This conference will also provide an overview of the Community-based Care Transitions Program (CCTP) and provide the opportunity for hospitals to connect with CBOs in their communities. Once a solicitation for the CCTP is published, proposals will be accepted on a rolling quarterly basis beginning in early 2011. II. Meeting Agenda The agenda for the December 3, 2010 meeting will include the following topic areas: • Overview of the CCTP under section 3026 of the Affordable Care Act. • The Business Case for Improving Care Transitions. • Building Community Support and Root Cause Analysis. • Overview of Care Transition Interventions. • Implementation of Care Transition Interventions—Successes and Challenges. Authority: Section 3026 of the Affordable Care Act Dated: October 21, 2010. Donald M. Berwick, Administrator, Centers for Medicare & Medicaid Services. [FR Doc. 2010–27789 Filed 10–29–10; 4:15 pm] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, November 18, 2010, 2 p.m. to November 18, 2010, 4 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the Federal Register on October 25, 2010, 75 FR 65498–65499. The meeting title has been changed to ‘‘RFA Panel: Translational Research in Pediatric and Obstetric Pharmacology’’. The meeting is closed to the public. E:\FR\FM\03NON1.SGM 03NON1

Agencies

[Federal Register Volume 75, Number 212 (Wednesday, November 3, 2010)]
[Notices]
[Pages 67749-67751]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-27728]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of Laboratories and Instrumented Initial Testing 
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing 
for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
Federal agencies of the Laboratories and Instrumented Initial Testing 
Facilities (IITF) currently certified to meet the standards of the 
Mandatory Guidelines for Federal Workplace Drug Testing Programs 
(Mandatory Guidelines). The Mandatory Guidelines were first published 
in the Federal Register on April 11, 1988 (53 FR 11970), and 
subsequently revised in the Federal Register on June 9, 1994 (59 FR 
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); 
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and 
on April 30, 2010 (75 FR 22809).
    A notice listing all currently certified Laboratories and 
Instrumented Initial Testing Facilities (IITF) is published in the 
Federal Register during the first week of each month. If any 
Laboratory/IITF's certification is suspended or revoked, the 
Laboratory/IITF will be omitted from subsequent lists until such time 
as it is restored to full certification under the Mandatory Guidelines.
    If any Laboratory/IITF has withdrawn from the HHS National 
Laboratory Certification Program (NLCP) during the past month, it will 
be listed at the end and will be omitted from the monthly listing 
thereafter.
    This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of 
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road, 
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).

[[Page 67750]]


SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially 
developed in accordance with Executive Order 12564 and section 503 of 
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace 
Drug Testing Programs,'' as amended in the revisions listed above, 
requires {or set{time}  strict standards that Laboratories and 
Instrumented Initial Testing Facilities (IITF) must meet in order to 
conduct drug and specimen validity tests on urine specimens for Federal 
agencies.
    To become certified, an applicant Laboratory/IITF must undergo 
three rounds of performance testing plus an on-site inspection. To 
maintain that certification, a Laboratory/IITF must participate in a 
quarterly performance testing program plus undergo periodic, on-site 
inspections.
    Laboratories and Instrumented Initial Testing Facilities (IITF) in 
the applicant stage of certification are not to be considered as 
meeting the minimum requirements described in the HHS Mandatory 
Guidelines. A Laboratory/IITF must have its letter of certification 
from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met 
minimum standards.
    In accordance with the Mandatory Guidelines dated November 25, 2008 
(73 FR 71858), the following Laboratories and Instrumented Initial 
Testing Facilities (IITF) meet the minimum standards to conduct drug 
and specimen validity tests on urine specimens:

Instrumented Initial Testing Facilities (IITF):

    None.

Laboratories:

    ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840/800-877-7016 (Formerly: Bayshore Clinical Laboratory).
    ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 
14624, 585-429-2264.
    Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, 
Memphis, TN 38118, 901-794-5770/888-290-1150.
    Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210, 
615-255-2400 (Formerly: Aegis Sciences Corporation, Aegis Analytical 
Laboratories, Inc.).
    Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-
361-8989/800-433-3823 (Formerly: Kroll Laboratory Specialists, Inc., 
Laboratory Specialists, Inc.).
    Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 
804-378-9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific 
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, 
Inc.).
    Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little 
Rock, AR 72209-7056, 501-202-2783 (Formerly: Forensic Toxicology 
Laboratory Baptist Medical Center).
    Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 
800-445-6917.
    Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 
229-671-2281.
    DrugScan, Inc. P.O. Box 2969, 1119 Mearns Road, Warminster, PA 
18974, 215-674-9310.
    DynaLIFE Dx *, 10150-102 St., Suite 200, Edmonton, Alberta, Canada 
T5J 5E2, 780-451-3702/800-661-9876 (Formerly: Dynacare Kasper Medical 
Laboratories).
    ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 
38655, 662-236-2609.
    Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, 
Canada N6A 1P4, 519-679-1630.
    Laboratory Corporation of America Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713-856-8288/800-800-2387.
    Laboratory Corporation of America Holdings, 69 First Ave., Raritan, 
NJ 08869, 908-526-2400/800-437-4986 (Formerly: Roche Biomedical 
Laboratories, Inc.).
    Laboratory Corporation of America Holdings, 1904 Alexander Drive, 
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984 (Formerly: 
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, 
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical 
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche 
Group).
    Laboratory Corporation of America Holdings, 1120 Main Street, 
Southaven, MS 38671, 866-827-8042/800-233-6339 (Formerly: LabCorp 
Occupational Testing Services, Inc.; MedExpress/National Laboratory 
Center).
    LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, 
KS 66219, 913-888-3927/800-873-8845 (Formerly: Quest Diagnostics 
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division 
of LabOne, Inc.,).
    Maxxam Analytics*, 6740 Campobello Road, Mississauga, ON, Canada 
L5N 2L8, 905-817-5700 (Formerly: Maxxam Analytics Inc., NOVAMANN 
(Ontario), Inc.).
    MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 
55112, 651-636-7466/800-832-3244.
    MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 
97232, 503-413-5295/800-950-5295.
    Minneapolis Veterans Affairs Medical Center, Forensic Toxicology 
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
    National Toxicology Laboratories, Inc., 1100 California Ave., 
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
    One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, 
Pasadena, TX 77504, 888-747-3774 (Formerly: University of Texas Medical 
Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology 
Laboratory).
    Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 
91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology 
Laboratory).
    Pathology Associates Medical Laboratories, 110 West Cliff Dr., 
Spokane, WA 99204, 509-755-8991/800-541-7891x7.
    Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 
858-643-5555.
    Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 
30084, 800-729-6432 (Formerly: SmithKline Beecham Clinical 
Laboratories; SmithKline Bio-Science Laboratories).
    Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 
19403, 610-631-4600/877-642-2216 (Formerly: SmithKline Beecham Clinical 
Laboratories; SmithKline Bio-Science Laboratories).
    Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 
91304, 800-877-2520 (Formerly: SmithKline Beecham Clinical 
Laboratories).
    S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 
87109, 505-727-6300/800-999-5227.
    South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South 
Bend, IN 46601, 574-234-4176 x1276.
    Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177, 
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
    St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., 
Oklahoma City, OK 73101, 405-272-7052.
    Sterling Reference Laboratories, 2617 East L Street, Tacoma, 
Washington 98421, 800-442-0438.
    Toxicology & Drug Monitoring Laboratory, University of Missouri 
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 
65203, 573-882-1273.

[[Page 67751]]

    Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 
33166, 305-593-2260.
    US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson 
St., Fort George G. Meade, MD 20755-5235, 301-677-7085.
    *The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the certification of 
those accredited Canadian laboratories will continue under DOT 
authority. The responsibility for conducting quarterly performance 
testing plus periodic on-site inspections of those LAPSA-accredited 
laboratories was transferred to the U.S. HHS, with the HHS' NLCP 
contractor continuing to have an active role in the performance testing 
and laboratory inspection processes. Other Canadian laboratories 
wishing to be considered for the NLCP may apply directly to the NLCP 
contractor just as U.S. laboratories do.
    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 30, 2010 (75 FR 22809). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS-certified laboratories and participate in the 
NLCP certification maintenance program.

    Dated: October 28, 2010.
Elaine Parry,
Director, Office of Management, Technology, and Operations, SAMHSA.
[FR Doc. 2010-27728 Filed 11-2-10; 8:45 am]
BILLING CODE 4162-20-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.